Abstract
Background In rapidly growing, high burden urban centers, identifying tuberculosis (TB) transmission hotspots and understanding potential impact of interventions can inform future control and prevention strategies.
Methods Using data on local demography, TB reports, and patient reporting patterns in Dhaka South City Corporation (DSCC) and Dhaka North City Corporation (DNCC), Bangladesh, between 2010 and 2017, we developed maps of TB reporting rates across wards in DSCC and DNCC and identified wards with high rates of reported TB (i.e. “hotspots”) in DSCC and DNCC. We developed ward-level transmission models and estimated the potential epidemiological impact of three TB interventions: active case finding (ACF), mass preventive therapy (PT), and a combination of ACF and PT, implemented either citywide or targeted to high-incidence hotspots.
Results There was substantial geographic heterogeneity in the estimated TB incidence in both DSCC and DNCC: incidence in the highest-incidence wards was over ten times higher than in the lowest-incidence wards in each city corporation. ACF, PT and combined ACF plus PT delivered to 10% of the population reduced TB incidence by a projected 7-9%, 13-15%, and 19-23% over five years, respectively. Targeting TB hotspots increased the projected reduction in TB incidence achieved by each intervention 1.4- to 1.8-fold.
Conclusions The geographical pattern of TB notifications suggests high levels of ongoing TB transmission in DSCC and DNCC, with substantial heterogeneity at the ward level. Interventions that reduce transmission are likely to be highly effective, and incorporating notification data at the local level can further improve intervention efficiency.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Global Health Bureau; Office of Infectious Diseases; and US Agency for International Development, through Challenge TB [AID-OAA-A-14-00029], and by the American People through the United States Agency for International Development (USAID). The contents are the responsibility of The Johns Hopkins University (JHU) and do not necessarily reflect the view of USAID or the United States Government.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB approval was not required for this study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data used in the manuscript will be made available.
